Molecular Partners (NASDAQ:MOLN) Shares Down 0.5% – What’s Next?

Molecular Partners AG (NASDAQ:MOLN)’s share price fell 0.5% during trading on Tuesday . The stock traded as low as $3.81 and last traded at $3.86. 13,897 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 19,646 shares. The stock had previously closed at $3.88.

Analyst Ratings Changes

Separately, Lifesci Capital initiated coverage on Molecular Partners in a research report on Tuesday, March 11th. They set an “outperform” rating and a $12.00 target price for the company.

Molecular Partners Price Performance

The firm’s 50-day moving average price is $4.68 and its 200-day moving average price is $5.14. The stock has a market cap of $158.07 million, a P/E ratio of -1.82 and a beta of 1.06.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. Sell-side analysts expect that Molecular Partners AG will post -1.93 earnings per share for the current year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL grew its position in Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,353,968 shares of the company’s stock after acquiring an additional 910,747 shares during the quarter. BVF Inc. IL owned 3.35% of Molecular Partners worth $6,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 26.55% of the stock is currently owned by hedge funds and other institutional investors.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.